1. Home
  2. IMNM vs GRDN Comparison

IMNM vs GRDN Comparison

Compare IMNM & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$25.64

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Guardian Pharmacy Services Inc.

GRDN

Guardian Pharmacy Services Inc.

HOLD

Current Price

$39.51

Market Cap

2.6B

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
GRDN
Founded
2006
2004
Country
United States
United States
Employees
N/A
3600
Industry
Medicinal Chemicals and Botanical Products
Retail-Drug Stores and Proprietary Stores
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.6B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
IMNM
GRDN
Price
$25.64
$39.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
5
Target Price
$32.80
$40.60
AVG Volume (30 Days)
1.1M
273.8K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
51.40
N/A
EPS
N/A
N/A
Revenue
$6,941,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1,127.34
$7.63
P/E Ratio
N/A
$117.77
Revenue Growth
N/A
N/A
52 Week Low
$8.67
$19.30
52 Week High
$27.65
$44.00

Technical Indicators

Market Signals
Indicator
IMNM
GRDN
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
IMNM
GRDN

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About GRDN Guardian Pharmacy Services Inc.

Guardian Pharmacy Services Inc is a pharmacy services company providing technology-enabled services to help residents of long-term health care facilities (LTCFs) adhere to appropriate drug regimens, reducing the cost of care and improving clinical outcomes. The Company provides high-touch clinical, drug dispensing, and administration services tailored to residents in assisted living facilities, behavioral health facilities, and group homes, while also serving residents in all types of LTCFs. It partners with residents, LTCFs, and health plan payors to help reduce errors in drug administration, manage drug regimens, and improve adherence. The Company derives its revenue mainly from the sale of pharmaceutical and medical products.

Share on Social Networks: